In the HER2-positive and triple negative breast cancer (TNBC) subgroups, no significant difference was noted in RFS between the two TP53 signature groups; however, it is noteworthy that no patient in the wt-signature group experienced recurrence (Supplemental Fig. 2E and F). The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.